Identification of New FLT3 Inhibitors That Potently Inhibit AML Cell Lines via an Azo Click-It/Staple-It Approach

ACS Medicinal Chemistry Letters
Xiaochu MaHerman O Sintim

Abstract

Acute myeloid leukemia (AML) is an aggressive malignancy with only a handful of therapeutic options. About 30% of AML patients harbor mutated FLT3 kinase, and thus, this cancer-driver has become a hotly pursued AML target. Herein we report a new class of FLT3 inhibitors, which potently inhibit the proliferation of acute myeloid leukemia (AML) cells at nanomolar concentrations.

References

Dec 14, 2002·Blood·Mustafa BenekliMeir Wetzler
Sep 13, 2003·Leukemia·M Levis, D Small
Nov 25, 2006·Hematology·Donald Small
Mar 16, 2007·Blood·Chunaram ChoudharyHubert Serve
Jul 7, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S DawoodM Cristofanilli
Jul 14, 2010·Oncogene·E WeisbergJ D Griffin
Mar 1, 2011·Radiology and Oncology·Tanja OvcaricekSimona Borstnar
Dec 11, 2013·Proceedings of the National Academy of Sciences of the United States of America·Catherine Choy Smith
Jun 3, 2014·Therapeutic Advances in Hematology·Seth A WanderAmir T Fathi
Sep 19, 2014·Expert Opinion on Therapeutic Targets·Heiko Konig, Mark Levis
Jun 27, 2015·Seminars in Hematology·Michael R Grunwald, Mark J Levis
Jan 24, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·T M KadiaH Kantarjian

❮ Previous
Next ❯

Citations

Jan 13, 2021·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Hyo In KimHyun Jin Choi
Aug 25, 2020·ACS Medicinal Chemistry Letters·Jisheng LiuQian Cai
Feb 19, 2020·Journal of Chemical Information and Modeling·Jonathan FineGaurav Chopra
Feb 26, 2020·ACS Omega·Elizabeth LarocqueHerman O Sintim

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Related Papers

Clinical Advances in Hematology & Oncology : H&O
Jeffrey E Lancet
[Rinshō ketsueki] The Japanese journal of clinical hematology
Hitoshi Kiyoi
Clinical Advances in Hematology & Oncology : H&O
Dwight Gary Gilliland
Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
Xue LiuGuangsen Zhang
Expert Opinion on Therapeutic Patents
Jongkook LeeSun-Young Han
© 2022 Meta ULC. All rights reserved